BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/7/2015 11:06:00 AM | Browse: 1213 | Download: 1775
Publication Name World Journal of Gastroenterology
Manuscript ID 11026
Country South Korea
Received
2014-04-30 12:51
Peer-Review Started
2014-04-30 14:08
To Make the First Decision
2014-05-29 19:01
Return for Revision
2014-06-05 14:48
Revised
2014-07-08 00:00
Second Decision
2014-07-25 09:15
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-07-25 09:36
Articles in Press
2014-07-25 09:59
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-12-23 14:46
Publish the Manuscript Online
2015-01-07 11:07
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Randomized Controlled Trial
Article Title Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies
Manuscript Source Unsolicited Manuscript
All Author List Hyun Jeong Lee, Jin Il Kim, Jin Soo Lee, Eun Jung Jun, Jung-Hwan Oh, Dae Young Cheung, Woo Chul Chung, Byung-Wook Kim and Sung Soo Kim
Funding Agency and Grant Number
Funding Agency Grant Number
Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology 2013R1A1A2062603
Corresponding Author Jin Il Kim, MD, PhD, Division of Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 62 Yeouido-dong, Yeongdeungpo-gu, Seoul 150-713, South Korea. jikim@catholic.ac.kr
Key Words Helicobacter pylori; Eradication; Drug resistance; Concomitant therapy; Sequential therapy
Core Tip A total 680 patients who were infected with Helicobacter pylori (H. pylori) were divided into 4 groups and each group was treated with a different eradication therapy. The eradication rates were 76.2%, 84.2%, 84.4% and 94.4% in the rabeprazole, amoxicillin and clarithromycin (PAC) group, the rabeprazole, amoxicillin and metronidazole group, the sequential group and the concomitant group. Comparing concomitant therapy and PAC therapy, the number needed to treat was 5.49. The eradication rate was 84.4% for the second-line therapy and 42.9% for the third-line therapy. The study was designed due to the high prevalence of H. pylori and gastric cancer and the recent marked increase in clarithromycin resistance.
Publish Date 2015-01-07 11:07
Citation Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC, Kim BW, Kim SS. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol 2015; 21(1): 351-359
URL http://www.wjgnet.com/1007-9327/full/v21/i1/351.htm
DOI http://dx.doi.org/10.3748/wjg.v21.i1.351
Full Article (PDF) WJG-21-351.pdf
Full Article (Word) WJG-21-351.doc
Manuscript File 11026-Review.docx
Answering Reviewers 11026-Answering reviewers.pdf
Biostatistics Review Certificate Biostatistician_Review_Report_20140430124206.pdf
Copyright License Agreement 11026-Copyright assignment.pdf
Institutional Review Board Approval Form or Document Ethics_Committee_20140430123035.jpg
Non-Native Speakers of English Editing Certificate 11026-Language certificate.pdf
Peer-review Report 11026-Peer reviews.pdf
Scientific Misconduct Check 11026-CrossCheck.jpg
Scientific Editor Work List 11026-Scientific editor work list.pdf